0.03
-10.43%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immunovia AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker IMMNOV.ST. It has been listed since 1 December 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 685,000 and a net loss of SEK 145.9m. At that date it held total assets of SEK 88.2m and shareholders' equity of SEK 64.7m.
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. The company is headquartered in Lund, Skane. The company went IPO on 2015-12-01. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Dec 2015
- Employees
- 67
- Website
- immunovia.com ↗
Leadership
Pay as last reported
- Dr. Peter AndersenIndependent Chairman of the BoardSEK 470,000
- Mr. Jeff BorcherdingPresident, Chief Executive OfficerSEK 6.6m
- Ms. Valerie Bogdan-powersIndependent DirectorSEK 212,000
- Ms. Melissa FarinaIndependent DirectorSEK 222,000
- Mr. Hans JohanssonIndependent DirectorSEK 260,000
- Mr. Michael LoefmanIndependent DirectorSEK 205,000
- Mr. Martin MollerIndependent DirectorSEK 220,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 31
- Environment
- 15
- Social
- 24
- Governance
- 55
- Women in the workforce
- 80%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immunovia AB (publ) possesses cutting-edge technology in the field of immunodiagnostics, specifically in the area of early detection of cancer through blood-based tests. This technology gives the company a competitive advantage in the market.
- The company has a dedicated team of researchers and scientists who continually work towards advancing its technology and developing new products. This focus on R&D ensures that Immunovia remains at the forefront of innovation.
Weaknesses
- Immunovia relies heavily on partnerships with hospitals and clinics for access to patient samples and test validation. Any disruption in these partnerships may negatively impact the company's operations and growth.
- As a relatively small company, Immunovia may face challenges in penetrating and expanding its presence in global markets. Limited resources for marketing and distribution could hinder the company's growth potential.
Opportunities
- With an increasing focus on early detection and personalized medicine, there is a growing demand for technologies that can accurately detect cancer at an early stage. Immunovia's innovative technology positions it well to capture this market opportunity.
- The company has the opportunity to expand its market reach to emerging markets, where there is a rising prevalence of cancer and growing healthcare infrastructure. By targeting these markets, Immunovia can tap into new revenue streams.
Threats
- The field of cancer diagnostics is highly competitive, with several established players and new entrants constantly emerging. Immunovia faces the threat of competitors developing similar or better technologies, potentially reducing its market share.
- The development and commercialization of medical devices and diagnostics are subject to strict regulatory guidelines. Compliance with these regulations and obtaining necessary approvals can be time-consuming and costly, posing a threat to Immunovia's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.